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CyberKnife robotic radiosurgeryPurpose: High precision radiosurgery demands comprehensive delivery-quality-assurance techniques.
The use of a liquid-filled ion-chamber-array for robotic-radiosurgery delivery-quality-assurance was
investigated and validated using several test scenarios and routine patient plans.
Methods and material: Preliminary evaluation consisted of beam profile validation and analysis of
source–detector-distance and beam-incidence-angle response dependence. The delivery-quality-
assurance analysis is performed in four steps: (1) Array-to-plan registration, (2) Evaluation with standard
Gamma-Index criteria (local-dose-difference 6 2%, distance-to-agreement 6 2 mm, pass-rateP 90%), (3)
Dose profile alignment and dose distribution shift until maximum pass-rate is found, and (4) Final eval-
uation with 1 mm distance-to-agreement criterion. Test scenarios consisted of intended phantom
misalignments, dose miscalibrations, and undelivered Monitor Units. Preliminary method validation
was performed on 55 clinical plans in five institutions.
Results: The 1000SRS profile measurements showed sufficient agreement compared with a
microDiamond detector for all collimator sizes. The relative response changes can be up to 2.2% per
10 cm source–detector-distance change, but remains within 1% for the clinically relevant source–
detector-distance range. Planned and measured dose under different beam-incidence-angles showed
deviations below 1% for angles between 0 and 80. Small-intended errors were detected by 1 mm
distance-to-agreement criterion while 2 mm criteria failed to reveal some of these deviations. All ana-
lyzed delivery-quality-assurance clinical patient plans were within our tight tolerance criteria.
Conclusion: We demonstrated that a high-resolution liquid-filled ion-chamber-array can be suitable for
robotic radiosurgery delivery-quality-assurance and that small errors can be detected with tight
distance-to-agreement criterion. Further improvement may come from beam specific correction for
incidence angle and source–detector-distance response.
 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Comprehensive delivery quality assurance (DQA) is required for
high-dose radiosurgery to ensure accurate treatment delivery and
hence patient safety. Accurate and sensitive dosimetric methods
and detailed procedures are needed both in daily routine QA and
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radiosurgery is delivered by complex systems such as the roboti-
cally steered CyberKnife (Accuray Incorporated, USA) [1,2]. The
CyberKnife uses registration of stereoscopic X-ray images to the
planning computer tomography (CT) to locate and position the
patient on the treatment couch. Patient position shifts in reference
to the calibrated imaging center are tracked and corrected by the
robot. Inverse treatment planning is based on sequential multi-
objective optimization, which generally results in an arrangement
of several non-isocentric non-coplanar beams of various sizes and
source–detector-distances (SDDs) generating complex dose distri-
butions with steep dose gradients. Commissioning and perfor-
mance testing of the CyberKnife have been widely reported [3–5]
and the quality assurance necessary for robotic radiosurgery was
summarized in the American Association of Physicists in Medicine
(AAPM) Task Group 135 report [6].
Radiochromic film measurement is the current method of
choice both for routine QA as well as specific validation of patient
treatment plans for the CyberKnife [6,7]. The commissioning and
validation for film based CyberKnife DQA using various test scenar-
ios [7] was recently reported and results confirmed that, by means
of accurate film-to-plan registration, maximum Gamma-Index
pass-rate search and tight distance-to-agreement (DTA) criteria,
small errors in beam delivery and system miscalibration can be
detected. However, some drawbacks of film based methods applied
to CyberKnife, remained unsolved: (1) absolute film dosimetry
requires additional ion-chamber verification and appears to have
an accuracy of no less than 3% [7] and (2) film DQA evaluation is
cumbersome and requires long wait times (up to several hours)
after irradiation. The generally long times required both to perform
and analyze patient specific film DQA may significantly reduce the
number of dosimetrically verified clinical treatment plans.
On the other hand, DQA for conventional linear accelerators
with Multi Leaf Collimators (MLC) is routinely performed using
two-dimensional ion-chamber or diode arrays [8–11]. However,
the diode or chamber spacing of these arrays (0.5–1.0 mm) is gen-
erally too large for the small CyberKnife beams. Recently, a new
high-resolution liquid-filled ion-chamber array (Octavius1000SRS,
PTW, Germany) with 2.5 mm chamber spacing at the center was
developed purposefully for small field radiosurgery DQA. The gen-
eral dosimetric properties of the 1000SRS are promising [12,13],
but specific questions regarding angular and dose-per-pulse
(DPP) dependences [14] originating from small non-coplanar
beams with variable SDD remain unanswered for the applicability
to CyberKnife DQA. Specifically, the following questions need to be
addressed before validating CyberKnife treatment plans using the
1000SRS:
(1) Is the 1000SRS chamber spacing (2.5 mm at the center)
appropriately sensitive for the small field sizes of the
CyberKnife (5–60 mm)?
(2) Does the DPP and thus SDD dependence of the 1000SRS
influence the DQA measurements for clinical CyberKnife
plans with variable SDDs (typically 80–90 cm)? Liquid filled
ion-chambers are subject to much larger recombination
effects [14]. Specifically, the volumetric recombination,
which refers to the recombination of two ions coming from
different ionization events, are dependent on dose rate and
therefore on the distance of the beam source and the detec-
tor [14].
(3) Are the different incident angles of a CyberKnife plan (typi-
cally 0–110) influencing the DQA measurements performed
using the 1000SRS? Array dose responses are generally
dependent on beam incidence angle, especially for lateral
beams passing through multiple diodes or chambers.
Various techniques such as synchronously rotating the arrayor using angle correction factors [15,16] have been imple-
mented in clinical routine. However, rotating the 1000SRS
synchronously with the CyberKnife is non-trivial due to
the six degrees of freedom of the robot.
In this study, a streamlined CyberKnife DQA process using the
Octavius 1000SRS detector was developed and evaluated. The
design of the study followed the scheme we had previously imple-
mented for film based DQA [7]. The test scenarios proposed for film
dosimetry were used with minor modifications to evaluate the
sensitivity of the proposed 1000SRS DQA method to system deliv-
ery errors and geometric misalignments. A benchmark will be
established for commissioning liquid-filled ion-chamber array-
based CyberKnife DQA and the results will be compared against
the current gold standard (film). Furthermore, new tests were
added to address the specific issues related to the use of the array,
such as DPP and angular dependence. The appropriate criteria for
Gamma-Index analysis were also evaluated in reference to our pre-
vious findings with film DQA [7] and the proposed tolerance levels
were validated on a large number of clinical treatment plans in
multiple institutions.2. Methods and materials
2.1. High-resolution liquid-filled ion-chamber array
The Octavius 1000SRS detector array consists of 977 MicroLion
liquid-filled ionization chambers that are arranged in a square
plane. The chamber has a sensitive volume of 2 mm3 and is filled
with iso-octane having a density of 0.688 g/cm3. The size of each
detector is 2.3  2.3  0.5 mm (2.65 mm3) and the spacing in the
high resolution inner area (5.5  5.5 cm2) is 2.5 mm (center to cen-
ter), whereas the spacing of the detector in low resolution outer
area (up to the full 11  11 cm2 measurement area) is 5 mm (cen-
ter to center). The properties and characteristics of the 1000SRS
have been thoroughly investigated for conventional linear acceler-
ators [12,13].2.2. Dosimetric analysis of the 1000SRS specific for CyberKnife DQA
To assess the sampling distance and resolution, the x and y pro-
files of the 12 collimated small circular CyberKnife beams (5, 7.5,
10, 12.5, 15, 20, 25, 30, 35, 40, 50, 60 mm) were measured with
the 1000SRS and compared to profiles measured in a water phan-
tom using a synthetic diamond detector (TM60019, PTW), which
was previously evaluated and validated for accurate CyberKnife
beam commissioning [17]. The TM60019 has a sensitive volume
of 0.004 mm3. The water phantom axis and the 1000SRS array were
positioned along the CyberKnife robotic coordinate system. The
TM60019 detector was aligned to the center of the field and posi-
tioned orthogonal to the beam direction. The x and y profiles were
measured at 5 cm water depth and a source–surface-distance of
80 cm. The 1000SRS measurements were performed in water
equivalent RW3 (PTW) in the same setup. The output factors mea-
sured with the 1000SRS were compared to measurements with the
TM60019 and with the small field diode E (TM60017, PTW). The
output factors for the TM60019 were uncorrected as the
TM60019 appears to require only small corrections relative to dose
in water [17] and the output factors for the TM60017 were cor-
rected by using Monte Carlo factors according to [18].
To assess the SDD response variability the array central cham-
ber was cross-calibrated in dose-to-water against a reference
SemiFlex 0.125 cm3 ion-chamber (PTW) using the 60 mm collima-
tor and varying the SDD from 60 cm to 120 cm, both for the cham-
ber and the array. The phantom build-up configurations varied
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measurements performed in the same center. Additionally, the
SDD dependence curves were also converted in a DPP response
curves using the center specific pulse repetition frequency (PRF)
and dose rate values and compared to previous publications [12].
To analyze the angular response we evaluated the reading of the
central chamber of the 1000SRS for each possible beam direction
(node) of an isocentric treatment plan and compared the measure-
ment to the standard treatment planning dose calculation (Ray
Tracing) for that beam.
2.3. Gamma Index analysis
Gamma-Index analysis was performed using VeriSoft (Version
6.1, PTW). The acceptance ellipsoid was defined by considering
the local percentage dose difference (LDD) and the distance-to-
agreement (DTA) criteria. In the following, we will simplify each
used combination as X%/Ymm where X indicates the LDD in per-
cent and Y the DTA in mm. Since the 1000SRS measurement area
is larger (11  11 cm) than the commonly used radiochromic
CyberKnife films (6  6 cm), we were able to increase the analyzed
dose levels from 50–100% to 20–100% as compared to our previous
work [7].
2.4. Array-based delivery quality assurance
For the DQA of clinical patient treatment plans, we projected
the beam arrangement onto the 1000SRS. The array was used add-
ing 1–3 cm RW3 build-up material that included a 1 cm RW3 thick
gold fiducial marker plate (PTW) screwed to the 1000SRS for accu-
rate CyberKnife X-ray image guidance. For dose calculation, the
1000SRS together with build-up was set to RW3 equivalent elec-
tron density (1.03 g/cm3 [13]) in the phantom CT scan setting.
The remaining part of the image was assumed to consist of air
equivalent electron density to compensate for CT artifacts from
the electronics. We recalculated the dose distribution for the phan-
tom plan using the standard RayTrace dose calculation algorithm.
Since VeriSoft assumes the central chamber to be coincident
with the dose calculation grid center, array-to-plan registration
was performed by aligning the center of the dose calculation box
to the central ion-chamber of the 1000SRS. The registration was
performed manually for each plan and visually checked using the
1000SRS phantom CT. The geometric accuracy and reproducibility
of the whole procedure is approximately 0.5 mm, thus larger than
the one achievable with film based methods [7].
Since a beam by beam angle and SDD correction is not yet pos-
sible in either VeriSoft or in the CyberKnife planning system we
were only able to correct the 1000SRS measurement by applying
an average beam SDD correction factor as determined during
cross-calibration.
For plan DQA evaluation, we adopted the following three-step
procedure from the previously published film-based DQA method
[7]:
(1) A preliminary comparison of the delivered and planned dose
distributions is performed after array-to-plan registration
using initially the 2%/2 mm 3D Gamma-Index criteria and
requiring a pass-rate above 90% according to the AAPM TG
135 [6]. We use the 3D Gamma-Index analysis due to uncer-
tainties in measurement plane definition on the phantom
CT.
(2) The contour-matching-based auto alignment function of
VeriSoft is used first in-plane in combination with the Maxc
search [7] second out-of-plane to determine the displace-
ment vector which optimizes the Gamma-Index passingrate. The maximum displacement tolerance was set to
1.5 mm, which includes the global beam delivery and
array-to-plan registration uncertainties.
(3) The required final tolerance was a pass-rate above 90% using
3%/1 mm for 2D Gamma-Index analysis. In order to evaluate
the limitations of the method, we also computed Gamma-
Index pass-rates for 2%/1 mm criteria.2.5. Sensitivity and reproducibility tests
The first test scenario was designed to study the array sensitiv-
ity to translational beam and plan shifts using the VeriSoft auto
alignment function. For the beam shift detection, beams with var-
ious sizes (5 mm, 35 mm, 60 mm) were vertically centered over the
central ion-chamber of the 1000SRS and shifted at 0.1 mm steps in
the superior-inferior and left–right direction moving the robot. At
each position, 100 Monitor Units (MU) was delivered and com-
pared to the reference un-shifted robot position using the auto
alignment function. For the plan shift detection, a standard spher-
ical isocentric CyberKnife End-2-End plan [6] was used. Before plan
delivery the phantom was shifted by 0.3, 0.5, 1.0 and 2.0 mm in
superior–inferior direction and the results were again compared
to the baseline un-shifted plan using the auto alignment function.
The second test scenario was designed to study the repro-
ducibility of beam delivery over time. A single 60 mm beam plan
was delivered 25 times over a period of one month including setup
re-positioning of the fiducial plate as well as of the liquid-filled
ion-chamber array on the treatment couch. The displacement of
the beam and the delivered dose were compared to a reference
delivery acquired at the beginning. As the 1000SRS absolute dose
response is dependent on temperature changes (yet not on pres-
sure changes) the room temperature was monitored and kept con-
stant during the measurements. We also measured and evaluated a
clinical plan multiple times at different days.2.6. Dose miscalibration and missing beams test
The third test scenario was a miscalibration of the system dose
output ranging from 0.5% to 5.0% in 0.5% steps. Again, a standard
spherical isocentric CyberKnife End-2-End plan [6] was delivered
with the clinical calibrated output (reference) and then with the
miscalibrated output.
The last test scenario was created to evaluate the sensitivity of
Gamma-Index analysis and the related proposed criteria to non-
delivered treatment beams. Total MU of 128 (0.8%), and 246
(1.5%), each from a single beam, and 374 (2.3%) from two beams
and 490 (3%) from three beams were removed from a complex
beam arrangement (total beams 170, total MU 16364). The
removed beams were initially pointed at the inferior section of
the complex target. The corresponding delivered dose distributions
were then compared to the original treatment plan dose calcula-
tion. Since this test was performed removing beams, it was
expected to yield some variations also in the shape of the delivered
dose distribution and thus allowed a sensitivity evaluation to both
dose-difference and distance-to-agreement criteria in Gamma-
Index analysis. Although the possibility of the CyberKnife treat-
ment system not delivering beams during treatment is remote,
the aim of the test was to simulate a gradually increasing differ-
ence between delivered and planned dose distributions to analyze
the sensitivity of 1000SRS-based DQA method. Similar approaches
have previously been reported for different delivery techniques
[7,9–11] and for film based DQA procedures [7].
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To validate the method independently 55 routine DQA tests of
clinical patient plans were performed in five different clinics with
various CyberKnife generations: (a) CyberKnife G3, Saphir Radio-
surgery Center Northern Germany, Güstrow, Germany, (b) Cyber-
Knife G4 (VSI), Saphir Radiosurgery Center Frankfurt am Main,
Germany, (c) CyberKnife G4, IFCA, Florence, Italy, (d) CyberKnife
G4, Greater Poland Cancer Centre, Poznan, Poland and (e)
CyberKnife M6 Series, Schwarzwald-Baar-Klinikum, Villingen-
Schwenningen, Germany. The phantom CT scan resolution varied
among the CyberKnife centers between 0.61 and 0.82 mm (left–
right, ant-pos) and 0.68 and 1.00 mm (inf-sup).
2.8. Comparison with film dosimetry
The study design was purposefully adopted following the
scheme we previously used for the validation of CyberKnife film
DQA [7]. The 1000SRS sensitivity to plan translational shifts, miss-
ing beams and dose miscalibration was tested following the same
procedures we used to evaluate the sensitivity of film dosimetry
[7], thus permitting a direct comparison between the twomethods.
The evaluation of clinical plans DQA was also performed adopting
rigorously the same method and Gamma-Index criteria used for
film dosimetry [7], thus enabling a meaningful comparison
between the Gamma-Index pass-rates obtained by the 1000SRS
and film DQA.
3. Results
3.1. Dosimetric analysis of the 1000SRS specific for CyberKnife DQA
The profile comparison measured with the 1000SRS and the
TM60019 showed Gamma-Index pass-rates of 91.9% (x-axis) and
97.0% (y-axis) for 0.5%/0.5 mm criteria and median local percent
dose differences of 0.11% (±2.4%, x-axis) and 0.10% (±2.5%, y-axis)
for all collimators (Fig. 1) confirming the applicability of the
liquid-filled ion-chamber array for the small CyberKnife beams.
The measured output factors with various CyberKnife systems
show an overall sufficient agreement (Fig. 2). The difference
between 1000SRS and TM60019 and TM60017 (Monte Carlo cor-
rected according to [18]) for 7.5 mm and 5 mm collimator was in
the order of 1.5% and 3.0%, respectively, agreeing well with previ-
ous publications on CyberKnife output factors [14,17,18]. As the
dose-per-pulse effect with smaller fields is in the order of 0.35%
[14] volume averaging effects in the 1000 SRS would probably be
responsible for the 3% under-response for the 5 mm collimator
output factor and warrant further investigation.Figure 1. Profile measurements along the robotic x (left) and y (right) axis with thThe dose response measurements at various SDD confirm the
DPP dependence of the 1000SRS and clinical correction factors nor-
malized at the nominal reference distance of 80 cm are shown for
the different detectors and CyberKnife (Fig. 3). Due to different PRF
and dose rates, the DPP value at 80 cm SDD is different from center
to center, but is consistent with different 1000SRS detectors. It is
essential to remark, that although the variability among the cali-
bration factors is large over the entire SDD range, between 80
and 90 cm SDD, which corresponds to the majority of beams in
clinical treatment plans, the SDD dependence is within 1% for all
considered CyberKnife systems and detectors.
Beams with incidence angles over 80 degree (indicated as lat-
eral beams in the following) demonstrated a high local dose differ-
ence (>10%) between the 1000SRS central dose measurement and
the plan dose calculation (Fig. 4). For angles smaller than 80,
which includes the majority of the CyberKnife beam angles, the
differences were generally small (mean local dose difference
0.74%). An average CyberKnife treatment plan has approximately
8% of its MU delivered by lateral beams (see section clinical patient
plans) which may result in a total local dose difference of approx-
imately 1.5%. For treatment plans with more relative MU (e.g., 20%)
from lateral directions the total local dose difference may poten-
tially raise to 3.0%, which needs to be considered when analyzing
the DQA measurements.3.2. Sensitivity and reproducibility tests
The 0.1 mm beam shifts introduced by moving the robot were
detected using the auto alignment function with an accuracy of
0.03 mm (mean absolute accuracy 0.01 mm in superior-inferior
and 0.02 mm in left–right direction) for various collimators. The
End-2-End plan shifts were detected by the auto alignment func-
tion with an accuracy of 0.15 mm (Table 1). The Gamma-Index
analysis performed before auto alignment with 2%/2 mm criteria
did not detect any shift (pass-rate < 90%) while 3%/1 mm criteria
yielded a pass-rate <90% only for the 1 mm and 2 mm shifts. The
sensitivity to translational shifts obtained by this test for the
1000SRS using the VeriSoft auto-alignment software was consis-
tent with previous reported results obtained by film dosimetry
applying the Maxc search method [7], which showed an accuracy
of 0.3 mm.
Repeating the beam delivery 25 times resulted in a mean and
maximum displacement to reference of 0.07 mm and 0.22 mm
(left–right) and 0.20 mm and 0.34 mm (inf–sup). The mean and
maximum displacement to reference measured with film (Daily
Automated Quality Assurance Test [6]) in the same time period
was 0.09 mm and 0.24 mm (left–right) and 0.15 mm and
0.37 mm (inf–sup) matching the results of the 1000SRS withine 1000SRS and the TM60019 with the 10 mm, 30 mm and 60 mm collimator.
Figure 2. Left: Output factors for the small CyberKnife (CK) fields measured by 1000SRS, TM60017 (diode E) and TM60019 (microDiamond). Right: Difference between the
various output factors. The output factors for the TM60019 were uncorrected [17] and the output factors for the TM60017 were corrected for using Monte Carlo factors
according to [18].
Figure 3. Left: relative calibration factors of the 1000SRS at various source–detector-distances (SDDs). The dose per pulse (DPP) at 80 cm SDD for the CyberKnife (CK) G3 was
0.72 mGy/pulse, for the CK G4 1.06 mGy/pulse and for the CK M6 0.83 mGy/pulse. Right: DPP dependence for various CK and arrays in comparison to Poppe et al. [12].
Figure 4. Beam incidence angle response for an iso-centric treatment plan with 60 mm collimator. Left: relative dose of dose calculation and array measurement (lines
indicate a polynomial fit function). Right: relative difference of the dose calculation and the measurement.
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0.18% for the 1000SRS with temperature control and 0.15% for a
reference ion-chamber (T30012, PTW) used for daily dose mea-
surements in the same time period. Repeating the delivery and
evaluation of a clinical plan at different times, the difference was
<3.0% in Gamma-Index pass-rate for both 3%/1 mm and 2%/1 mm
criteria, which is in agreement with published literature [12,13].3.3. Dose miscalibration and missing beams test
The analysis with various Gamma-Index criteria of the intro-
duced system absolute dose miscalibrations is summarized in
Fig. 5. Gamma-Index analysis with 2%/2 mm criteria did not indi-
cate any miscalibrations <4% while 1%, 2% and 3% local dose differ-
ence with 1 mm distance to agreement detected 2.0%, 2.5% and
Table 1
Gamma analysis of End-2-End plans shifted before delivery.
1000SRS Before alignment Auto alignment
Shift Gamma pass-rate
S/I 2%/2 mm 3%/1 mm L/R S/I
(mm) % % (mm) (mm)
0.30 100.00 100.00 0.02 0.35
0.50 100.00 100.00 0.00 0.49
1.00 100.00 76.50 0.00 1.15
2.00 92.50 38.50 0.00 2.00
S/I = Superior/Inferior, L/R = Left/Right.
Table 2
Gamma analysis with and without missing the delivery of beams.
Missing Before alignment After alignment
Gamma pass-rate Auto alignment Gamma pass-rate
MU 2%/2 mm L/R S/I 3%/1 mm 2%/1 mm
(%) % (mm) (mm) % %
0.00 94.30 0.65 0.64 90.10 80.10
0.80 93.40 0.80 0.84 86.10 79.10
1.50 83.40 0.55 1.05 72.50 67.40
2.30 79.60 0.65 1.14 67.30 63.00
3.00 79.10 0.69 1.10 66.40 62.20
MU = Monitor Units, S/I = Superior/Inferior, L/R = Left/Right.
Figure 6. 3%/1 mm Gamma-Index pass-rate after alignment as a function of ratio of
lateral beams divided into complex shaped (black triangles) and spherical shaped
(open circles) dose distributions (lines indicate a linear fit function for each of the
data sets).
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found to be the most sensitive criteria (steepest slope) for system
absolute dose miscalibration detection for our test scenario.
The analysis performed for increasing number of missing beams
during plan delivery is summarized in Table 2. The Gamma-Index
analysis with 2%/2 mm detected missing MU above 1.5% (pass-
rate < 90%) while the 3%/1 mm criteria after auto alignment indi-
cated missing MU above 0.8%. However, as the test scenario had
a complex dose distribution with a high number of lateral beams
(compare Fig. 6) the reference pass-rate with 3%/1 mmwas already
low (90.1%) and 2%/1 mm could not be used as criteria, yielding a
passing rate below 90% already for the reference delivery. Further-
more, with higher missing MU during plan delivery the auto align-
ment function also showed larger shifts due to the changes in the
measured isodose lines. Nevertheless, the drop in pass-rate was
the steepest for 3%/1 mm Gamma-Index criteria. The results con-
firmed what was reported for film dosimetry with a similar test:
film showed the higher sensitivity to this test using 1 mm DTA,
while the 2%/2 mm criteria could only detect higher differences
(5%) [7].
3.4. Clinical patient plans
The DQA results of clinical patient plans are summarized in
Table 3. Before analysis, a center specific average SDD correction
factor was applied to each measurement, as specified in the mate-
rials and method section. After array-to-plan registration, 2%/2 mm
Gamma-Index analysis yielded pass-rates above 90% for 54 out of
55 cases, where a non-optimal registration may have been the
cause for failure in the remaining case. Performing auto alignment
and Maxc search, we obtained shifts <1.5 mm (mean absolute,
0.48 mm) in all cases. Final results yielded 3%/1 mm pass-rates
above 90% (mean, 95.8%) for all cases. Gamma-Index analysis with
2%/1 mm yielded pass-rates above 90% (mean, 90.8%) for 30 out ofFigure 5. Gamma analysis of various absolute dose miscalibration tests (lines
indicate a linear fit function for each of the data sets).55 cases (54.5%) and above 80% for 54 out of 55 cases (98.2%). It
may be noted that for some cases the pass-rate for 2D Gamma
and 2%/1 mm criteria is higher than for 3D Gamma and
2%/2 mm, which is again caused by non-optimal registration. Data
previously obtained for film dosimetry on a similar sample (33
plans) [7] yielded slightly lower passing rates. For 3%/1 mm the
film Gamma-Index pass rate was above 90% in only 83% of cases
(mean 94.5%). It must be highlighted that the isodose threshold
used for film analysis was 50% due to the limited dimensions of
the phantom, as compared to a 20% threshold adopted in the pre-
sent work.
The pass-rates seem to be independent of location (head or
body), number of beams, collimator sizes, maximum doses, or per-
forming CyberKnife center. The pass-rates for the extracranial
cases were however strongly influenced by adding the average
SDD correction factor (mean pass-rate 87.9% without versus
93.3% with average SDD correction factor) when the CyberKnife
showed stronger DPP dependencies (CyberKnife G4, compare
Fig. 3). At first sight, the pass-rates also seem to be not influenced
by the percentage of MU delivered from lateral beams (incidence
angle above 80). However, considering the complexity of the dose
distribution (spherical versus complex shape), a trend towards
lower pass-rates with increasing percent MU from lateral beams
can be observed for complex shaped but not for spherical dose dis-
tributions (Fig. 6).
4. Discussion
Quality assurance (QA) using radiochromic film is routine prac-
tice for robotic radiosurgery [5–7]. Absolute film dosimetry for
CyberKnife delivery quality assurance has been shown to yield
Table 3
Gamma analysis of routine patient plans.
No. Location Beams Collimator Max 3D Gamma Auto alignment Max (c) 2D Gamma Angle >80 Mean SDD
Dose 2%/2 mm L/R S/I A/P 3%/1 mm 2%/1 mm
(mm) (cGy) (%) (mm) (mm) (mm) (%) (%) (% MU) (cm)
1 Body 202 15, 25, 35 989 99.9 0.08 0.14 0.00 99.3 96.5 4.0 90.9
2 Body 147 10, 20, 30 1503 97.8 0.31 1.12 0.68 94.7 88.5 0.0 89.3
3 Body 156 12.5, 20 1530 94.8 0.88 1.30 0.68 98.3 92.2 1.6 91.0
4 Body 171 15, 20 1798 95.8 0.27 0.45 1.36 93.9 86.1 0.0 89.3
5 Body 160 15, 30, 40 616 85.9 0.67 1.00 1.36 96.3 88.4 10.0 91.2
6 Body 141 15, 25 886 97.4 0.15 0.83 0.00 97.9 90.7 0.0 89.4
7 Body 113 20, 30 1371 94.7 0.49 0.83 0.68 93.8 85.3 5.0 89.8
8 Body 132 10, 15, 25 1756 93.3 0.30 0.20 1.36 92.3 81.0 0.0 89.6
9 Body 188 10, 20, 30 2171 99.1 0.31 0.61 0.00 96.7 90.1 2.2 89.1
10 Body 149 12.5, 25 1362 97.8 0.05 0.57 0.00 94.5 84.8 0.0 91.0
11 Body 186 15, 35 1591 91.3 0.13 1.20 0.68 97.4 88.4 1.8 89.5
12 Body 175 25, 50 1195 91.4 0.19 0.41 1.36 98.5 92.0 0.0 90.7
13 Body 168 10, 20, 35 1107 95.0 1.07 0.23 0.00 91.0 84.3 0.0 89.3
14 Body 151 7.5, 15, 25 1164 96.5 0.31 0.21 0.68 92.7 91.3 2.4 89.3
15 Body 166 20 2438 96.7 0.86 1.41 0.68 99.7 98.7 7.8 89.2
16 Head 142 10, 20 1274 95.7 1.44 0.01 0.00 90.6 83.7 8.2 83.5
17 Head 120 12.5, 20 833 93.9 0.17 1.10 0.68 93.9 82.7 4.9 80.6
18 Head 106 15, 20 1802 96.0 0.00 0.00 0.68 94.9 87.5 2.7 84.7
19 Body 169 20, 35 3092 100.0 0.54 0.50 1.22 100.0 99.5 0.0 89.2
20 Body 144 40 1810 97.5 0.65 0.26 1.22 99.1 96.9 5.1 89.9
21 Body 133 25 1282 99.5 0.62 0.29 1.22 99.7 98.1 2.7 89.5
22 Body 143 15 2624 97.4 0.23 0.25 0.61 94.8 87.5 10.9 90.2
23 Body 123 15, 25 1843 94.0 0.92 0.34 1.22 91.3 85.3 13.4 89.1
24 Body 101 20, 35 3959 95.3 0.26 0.22 0.61 90.5 84.6 14.5 90.9
25 Body 73 35 3564 98.7 0.26 0.91 0.61 93.8 92.4 4.4 91.9
26 Body 133 12.5, 25 1905 96.3 0.61 0.88 1.22 94.0 88.9 0.0 89.8
27 Body 168 20, 35 1310 94.9 0.37 0.96 0.61 92.0 86.6 2.6 90.7
28 Body 41 20 2563 100.0 0.13 0.19 0.00 99.0 90.1 7.4 94.1
29 Body 39 20 2867 100.0 0.81 0.37 1.22 100.0 97.1 0.0 92.2
30 Body 56 25 3195 97.8 0.39 0.50 0.00 97.8 86.2 10.6 90.5
31 Body 160 30, 40 2799 90.9 0.85 0.75 1.22 96.0 91.0 3.0 92.1
32 Body 150 20 2796 98.5 0.45 0.21 0.00 94.5 90.7 8.8 90.5
33 Body 136 20, 35 3932 94.3 0.81 1.01 1.22 96.1 92.8 6.6 90.8
34 Body 75 35 4522 100.0 0.05 0.25 0.00 100.0 99.7 0.0 92.4
35 Body 131 40 3880 99.8 0.24 0.53 0.61 97.5 91.3 0.0 90.7
36 Head 144 10, 15 2508 100.0 0.22 0.04 0.00 99.4 99.4 17.2 79.8
37 Head 199 7.5, 12.5 1801 98.9 0.33 0.11 0.00 97.8 98.6 18.8 80.4
38 Head 151 12.5, 25 883 96.6 0.13 0.31 0.00 90.5 82.5 16.9 82.9
39 Head 166 7.5, 12.5, 20 744 99.6 0.59 0.37 0.86 97.8 96.0 21.7 80.7
40 Head 117 7.5, 15 2829 100.0 0.29 0.09 0.86 100.0 100.0 16.6 80.7
41 Head 133 5, 20 582 100.0 0.23 0.16 0.00 98.6 97.8 13.7 80.1
42 Head 174 7.5, 12.5 3095 100.0 0.57 0.07 0.86 100.0 100.0 15.2 81.1
43 Head 211 15, 30 694 98.7 0.20 0.31 0.00 97.8 95.0 16.6 81.4
44 Head 183 10, 15 2585 100.0 0.24 0.38 0.86 99.0 96.9 19.0 84.4
45 Head 189 5, 7.5 590 97.5 0.05 0.89 0.00 91.5 89.1 8.9 79.7
46 Body 150 25, 35, 50 2953 93.6 0.63 0.11 0.86 98.4 94.2 0.0 86.8
47 Body 115 20, 30, 40 810 96.3 0.09 0.07 0.86 91.3 87.4 16.4 85.1
48 Body 162 10, 15, 20 1324 98.6 0.73 0.14 0.86 91.5 87.1 17.6 79.9
49 Body 141 20, 30, 40, 60 1230 93.0 0.77 0.10 0.00 91.7 82.9 13.8 88.1
50 Body 25 20 740 100.0 0.06 0.09 0.00 97.3 97.3 15.6 91.8
51 Body 93 12.5, 25 1652 99.7 0.24 0.50 0.00 96.6 94.2 17.0 86.4
52 Body 161 20, 30, 40 1272 90.5 0.64 0.15 0.00 92.3 83.2 17.8 88.3
53 Body 136 10, 25 3267 100.0 0.60 0.55 0.00 99.6 98.5 0.0 85.7
54 Body 135 10, 25 633 96.5 0.39 0.13 0.00 93.0 88.7 13.7 82.8
55 Body 151 30, 40, 50, 60 2588 92.1 0.23 0.60 0.86 92.9 75.6 19.8 82.5
Max 211 4522 100.0 1.44 1.41 1.36 100.0 100.0 21.7 94.1
Min 25 582 85.9 1.07 1.00 1.36 90.5 75.6 0.0 79.7
Average 140 1929 96.7 0.01 0.28 0.16 95.8 90.8 7.9 87.5
MU = Monitor Units, S/I = Superior/Inferior, L/R = Left/Right, A/P = Anterior/Posterior, SDD = source–detector-distance.
2%/2 mm 3D Gamma-Index criteria was used after registration, but before alignment due to uncertainties in measurement plane definition on the phantom CT. 3% and 2%/
1 mm 2D Gamma-Index criteria was used after alignment in all three directions to evaluate the agreement of the calculated and measured dose distributions.
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tight DTA criteria (1 mm) [7]. Although the results obtained with
films for clinical DQA are encouraging and permit the use of
3%/1 mm Gamma-Index criteria in most cases, film dosimetry
remains cumbersome and we highlighted in our previous publica-
tion [7] the limitations and uncertainties related to absolute dose
calibration and required long waiting times. For verification of dosedistributions, generally diode or ion-chamber arrays are used, e.g.,
for IMRT and VMAT, often in combination with rotating phantoms
[11] or angular correction factors to minimize the variation of
detector angular response [15,16]. For the CyberKnife with its
non-isocentric non-coplanar beam arrangements, the usefulness
of planar ion-chamber arrays and cylindrical diode arrays has been
recently investigated [20] while rotating phantoms currently do
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and the increasing demand for high quality DQA measurements
we evaluated a CyberKnife DQA procedure which we previously
developed for film dosimetry [7] using the high resolution Octavius
1000SRS detector. The rationale was to use the same study design
adopted for film dosimetry hence permitting a comparison
between the two methods. To this purpose, following our previous
study we provided a range of test scenarios to commission the
CyberKnife DQA method using the 1000SRS array and to estimate
the related sensitivity, similar to currently recommended proce-
dures for IMRT and VMAT [8–11].
Preliminarily, we evaluated the dosimetric characteristics of the
1000SRS for the small CyberKnife beams specifically for CyberKnife
DQA and found that the measurements both for the profiles and
the output factors match the synthetic diamond detector closely,
which was previously evaluated for CyberKnife commissioning
[15]. Furthermore, we investigated and confirmed in a multi-site
context the source–detector-distance (SDD) and dose-per-pulse
(DPP) dependence of the 1000SRS array when used for the Cyber-
Knife beams. This has previously been reported for the MicroLion
chamber and for the 1000SRS array for other delivery systems
[12–14]. Following the results obtained in this study, we high-
lighted the necessity of acquiring a center specific SDD response
curve prior to the clinical use of the array and the use of a SDD
dependent cross-calibration factor, considering that the beam
SDD can vary during CyberKnife plan delivery. As a first approxi-
mation of the SDD response correction, we propose to calculate
an average plan SDD value and to apply the corresponding multi-
plicative correction factor derived from the SDD response curve.
A more rigorous approach would require a SDD correction per-
formed on a beam by beam basis, but dedicated software would
have to be developed for this purpose to permit the use in clinical
routine. It is also interesting to highlight that without an average
plan SDD correction factor the results of the extracranial cases
for the CyberKnife G4 (compare Fig. 3) would have resulted in a
significant reduction in Gamma-Index pass-rate for almost all
cases (mean pass-rate 87.9% versus 93.3%, p < 0.05). Dose differ-
ences due to beam incidence angle were also investigate and we
found larger (>10%) differences only with angles greater than
80 . This is usually a small percentage (average 7.9%, maximum
21.7% for the examined 55 cases) of the CyberKnife beams for most
clinical cases. However for the moment it is not possible to give an
accurate estimate of the error introduced by the angular depen-
dence for plans which exhibits a not negligible (>10%) percentage
of beam angles above 80 . The possibility however exists for the
user to switch off beams corresponding to angles above 80  pur-
posefully for DQA, thus delivering for verification a plan slightly
modified as compared to the clinical plan, but at the same time
removing all uncertainties due to the angular dependence.
Given the uncertainties due to SSD variations and incidence
angle response differences we investigated if the previously deter-
mined Gamma-Index criteria for robotic radiosurgery film DQA [7]
are adequate when using the 1000SRS. The proposed Gamma-
Index criteria by the AAPM TG 135 for film based DQA are 2% dose
difference (without reference to global or local dose) and 2 mm
distance-to-agreement, requiring a pass-rate above 90% [6]. Similar
criteria were also used for a recent study involving a planar and a
cylindrical array for CyberKnife DQA [20]. However, from our pre-
vious analysis performed for film DQA it was demonstrated that
with 2%/2 mm criteria small errors during CyberKnife beam deliv-
ery remain undetected [7]. It was suggested to use accurate
measurement-to-plan registration, local dose difference and
distance-to-agreement criteria respectively of 3% and 1 mm to take
better into account the CyberKnife geometric accuracy. We criti-
cally analyzed the possibility to adopt the same criteria also for
1000SRS DQA, both in preliminary test scenarios and clinical plans.The test scenarios with intended beam and plan shifts and the
reproducibility tests demonstrated a high reliability of the
1000SRS measurements matching the current gold standard (film).
Similar to previous findings with film, we were able to demon-
strate the advantages of tighter DTA criteria (1 mm rather than
2 mm). The used test cases highlighted that the selection of a tigh-
ter DTA enhanced the sensitivity of the DQAmethod to small deliv-
ery errors, such as small shifts or missing beams, which would
have been undetected by Gamma-Index analysis with 2 mm DTA.
Moreover, compared to what was previously reported for film
DQA, the 1000SRS alone was (as expected) able to detect small sys-
tem absolute dose miscalibration (2%), again with higher sensitiv-
ity when using tighter DTA criteria.
Analysis of clinical treatment plans were performed indepen-
dently at five different CyberKnife centers and confirmed the
robustness of the proposed method for application to CyberKnife
DQA. A multi-site evaluation emphasizes the strength of the
obtained results since it permits to rule out user’s dependent errors
as well as all possible biases related to the clinical implementation
in a single center. For 55 cases over the 5 enrolled centers, the auto
alignment and the Maxc search was within tolerance
(shift < 1.5 mm) in all examined DQA deliveries, confirming that
1.5 mm is an adequate tolerance level for the maximum allowed
shift due to the combined uncertainties of registration and beam
alignment. This is also a confirmation that the dedicated fiducial
plate warrants an adequate tracking accuracy. After alignment,
all cases yielded pass-rates above 90% for 3%/1 mm and this result
was consistent with the previously reported results obtained by
film dosimetry on a 30 plans sample [7]. Although 1000SRS and
film DQA tests were not performed using the same clinical plans,
the size of the two samples (55 and 30), the inclusion of plans cre-
ated for a variety of treatment sites, and the multi-site context of
both studies make a comparison between the two sets of results
meaningful. It is interesting also to remark that 98.2% of the cases
yielded pass-rates above 80% for 2%/1 mm. These results indicated
the possibility to use Gamma-Index criteria that are tighter than
those proposed for lower resolution array based CyberKnife DQA
[20] and potentially even tighter than the criteria we recently sug-
gested for film based CyberKnife DQA [7], permitting to decrease
the dose difference criteria from 3% to 2% with 1 mm DTA.
However, due to the uncertainties related to beam angle and DPP
dependence, which are only partially corrected for in our method,
the adoption of a 2% dose difference criteria requires caution and
further investigation. In the DQA analysis, we were able to include
lower isodoses, setting the threshold to 20% instead of 50%. This
was previously not possible using accurate film dosimetry [7]
due to the small dimensions of the dedicated CyberKnife Ball Cube
II phantom.
The Gamma-Index pass-rates for the 1000SRS DQA analysis
showed a decrease with increasing ratio of lateral beams, however
only for complex shaped dose distributions. The effect was practi-
cally not visible for spherical dose distribution. This suggests that
for standard spherical dose distribution lower local dose difference
criteria (i.e., 1–2%) may be used.
Some drawbacks and limitations of the proposed method
should be highlighted. Array-to-plan registration is currently not
optimal for a precise estimation of the global geometric delivery
accuracy. The registration method presented in this work was
based on a manual centering of the dose grid on the 1000SRS array
CT scan and is expected to have a higher uncertainty compared to
film-to-plan registration (0.5 mm vs. 0.2 mm [7]). It was rather
cumbersome to manually define the correct measurement plane
and the correct location of the central ion-chamber of the array.
The possibility of an automatic registration method using well
defined landmarks or an artificial phantom CT scan are highly
desirable to further decrease the uncertainty in cross-calibration
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increase the DQA accuracy. A dedicated correction function for the
angular dependence applied to lateral beams would also be highly
desirable, since it is currently not possible to discern angular
response errors in the DQA results. Similarly, the results of
1000SRS based DQA may be further improved by applying a beam
by beam SDD correction during dose calculation instead of an aver-
age correction factor, which is under current investigation. Due to
those remaining unsolved corrections (beam angle and DPP) a
decrease to 2% LDD, although attractive, is not fully justified for
the moment, especially with complex plans that have a higher
number of lateral beams.
It would also be interesting to investigate errors incorporated
directly into clinical plans. However, introducing errors such as
modified angles or beam sizes, which have been simulated for
other techniques [9,10] is currently not feasible due to the Cyber-
Knife system architecture. We therefore think that the use of our
test scenarios is a valuable compromise for a first validation of
the method sensitivity.
Lastly, caution is advised with the 1000SRS when verifying
treatment plans that have very small target volumes and use the
smallest collimators (5 mm and 7.5 mm). Due to volume effects,
the resolution of the 1000SRS and the Gamma-Index analysis
method errors in small field verification could be large and need
to be evaluated in more detail. Other methods such as DVH- or spa-
tial pixel-dose analysis [19,21,22] and the possibility to analyze
passing rate as a function of gamma tolerance or gamma distance
may be more meaningful than Gamma-Index analysis alone.
Nevertheless, the presented results highlight that 1000SRS can be
used for reliable CyberKnife DQA, and it is a valid alternative to
film, permitting to overcome film dosimetry limitations in terms
of long waiting times and absolute dose uncertainties. Automatic
array-to-plan registration and a beam-by-beam SDD and angle cor-
rection are under investigation and may expedite the DQA analysis,
alleviating QA burden while increasing the number of clinical plans
to be verified. A discussion on the necessary frequency for the labo-
rious CyberKnife DQA is beyond the scope of this paper, but
requires further investigation [23].
5. Conclusion
We demonstrated that a high-resolution liquid-filled ion-
chamber array is suitable for robotic radiosurgery DQA and that
despite non-corrected beam angle response differences and vari-
able SDD the results were comparable to those obtained by film
dosimetry. We also demonstrated that small system errors can
be detected with tight Gamma-Index criteria and we provided var-
ious test scenarios to validate the detector sensitivity for robotic
radiosurgery delivery quality assurance. Our proposed tolerance
levels were validated on a considerable number of clinical plans
obtained at five different centers. Further improvement may come
from beam specific angle and SDD corrections.
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